Approaches for application of sub and supercritical fluid extraction for quantification of Orbifloxacin (cas 113617-63-3) from plasma and milk: Application to disposition kinetics

Add time:08/23/2019    Source:sciencedirect.com

Since its extensive development in the early 1980s, SFE has attracted considerable attention as a sample-preparation procedure. However, other different sample preparation procedures, including precipitation, liquid- and/or solid-phase extraction in biological fluids, also remain in use. In this investigation, SFE was introduced to isolate and identify Orbifloxacin (cas 113617-63-3) from plasma and milk. Four parameters, including the temperature and the pressure of supercritical fluid, modifier ratios, and dynamic extraction time, were evaluated and optimized to obtain the best yield of the analyte from the biological fluids. Determinations of the orbifloxacin (OBFX) in the extracts were carried out using HPLC-FLD. The optimum conditions of the extraction process that yielded the maximum analyte extraction efficiencies were 150 °C vs. 60 °C, 250 kg cm−2, 30% vs. 35% methanol, and 40 min vs. 20 min, for plasma and milk, respectively. The linearity of the calibration curves as well as the instrument LODs/LOQs were evaluated. Good linearity (at least r2 ≥ 0.999) of the calibration curves was obtained over the range from 0.2 to 0.01 μg mL−1. The method showed a good recovery rate (74.2–127.73%) and precision (RSDs: 1.64–20%). The instrumental LOD and LOQ values were 0.004 μg mL−1 vs. 0.01 μg mL−1 or 0.006 μg mL−1 vs. 0.02 μg mL−1, for plasma and milk, respectively. The method was successfully applied to estimate the pharmacokinetic variables of orbifloxacin in lactating does. To the best of our knowledge, this is the first time that SFE has been applied to isolate an antimicrobial agent from biological fluids. This method is promising for clinical applications and for pharmacokinetic studies of various pharmaceuticals in biological fluids.

We also recommend Trading Suppliers and Manufacturers of Orbifloxacin (cas 113617-63-3). Pls Click Website Link as below: cas 113617-63-3 suppliers

Prev:In vitro antimicrobial activity of Orbifloxacin (cas 113617-63-3) against Staphylococcus intermedius isolates from canine skin and ear infections
Next:ReviewHow to direct the fatty acid biosynthesis towards polyhydroxyalkanoates production?)